Elsevier

Endocrine Practice

Volume 19, Issue 3, May–June 2013, Pages 536-557
Endocrine Practice

AACE Consensus Statement
American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary

https://doi.org/10.4158/EP13176.CSGet rights and content

Section snippets

EXECUTIVE SUMMARY

This new algorithm for the comprehensive management of persons with type 2 diabetes mellitus (T2DM) has been developed to provide clinicians with a practical guide that considers the whole patient, the spectrum of risks and complications for the patient, and evidence-based approaches to treatment. In addition to advocating for gly- cemic control so as to reduce microvascular complications, this document focuses on obesity and prediabetes as the underlying risk factors for diabetes and

DISCLOSURE

Dr. Alan J. Garber reports that he is on the Advisory Board for Novo Nordisk, Merck, Halozyme, Janssen, Takeda, and Vivus. He is a speaker for Novo Nordisk, Merck, Santarus, Janssen, and Vivus. He is also a consultant for Novo Nordisk, Merck, Santarus, Takeda, Tethys, and Vivus.

Dr. Martin Julian Abrahamson reports that he is on the Advisory Board for Novo Nordisk, Boehringer Ingelheim and Halozyme.

Dr. Joshua I. Barzilay reports that he does not have any relevant financial relationships with any

First page preview

First page preview
Click to open first page preview

REFERENCES (109)

  • LeahyJ.L.

    Insulin therapy in type 2 diabetes mellitus

    Endocrinol Metab Clin North Am

    (2012)
  • CorraoG. et al.

    A meta-analysis of alcohol consumption and the risk of 15 diseases

    Prev Med

    (2004)
  • RidkerP.M. et al.

    Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

    J Am Coll Cardiol

    (2005)
  • CannonC.P. et al.

    Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

    J Am Coll Cardiol

    (2006)
  • SnidermanA.D.

    Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice

    J Clin Lipidol

    (2008)
  • RosensonR.S. et al.

    Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes

    Atherosclerosis

    (2009)
  • ButlerA.E. et al.

    Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

    Diabetes

    (2003)
  • BrayG.A. et al.

    Medical therapy for the patient with obesity

    Circulation

    (2012)
  • KipK.E. et al.

    Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study

    Circulation

    (2004)
  • AllisonD.B. et al.

    Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

    Obesity (Silver Spring)

    (2012)
  • GarveyW.T. et al.

    Low-dose controlled-release phentermine/topiramate (PHEN/TPM CR) for weight loss and management of type 2 diabetes mellitus (T2DM).In: Program of the 28th annual meeting of the Obesity Society

    Endocr Pract

    (October 8-12, 2010)
  • O'NeilP.M. et al.

    Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

    Obesity (Silver Spring)

    (2012)
  • SmithS.R. et al.

    Multicenter, placebo-controlled trial of lorcaserin for weight management

    N Engl J Med

    (2010)
  • FDA approves Invokana to treat type 2 diabetes-First in a new class of diabetes drugs. Available at

  • ChiassonJ.L. et al.

    The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial

    Ann Intern Med

    (1994)
  • GersteinH.C. et al.

    Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

    Lancet

    (2006)
  • KnowlerW.C. et al.

    Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

    Diabetes

    (2005)
  • InzucchiS.E. et al.

    Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    Diabetes Care

    (2012)
  • DuckworthW. et al.

    Glucose control and vascular complications in veterans with type 2 diabetes

    N Engl J Med

    (2009)
  • GersteinH.C. et al.

    Effects of intensive glucose lowering in type 2 diabetes

    N Engl J Med

    (2008)
  • BaileyC.J. et al.

    Metformin

    N Engl J Med

    (1996)
  • KahnS.E. et al.

    Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

    N Engl J Med

    (2006)
  • RoumieC.L. et al.

    Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study

    Ann Intern Med

    (2012)
  • PhungO.J. et al.

    Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

    JAMA

    (2010)
  • DeaconC.F. et al.

    Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

    Diabetes Obes Metab

    (2012)
  • LeechC.A. et al.

    Facilitation of b-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac

    Islets

    (2010)
  • DeaconC.F.

    Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

    Diabetes Obes Metab

    (2011)
  • RosakC. et al.

    Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

    Diabetes Metab Syndr Obes

    (2012)
  • HanefeldM. et al.

    Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

    Eur Heart J

    (2004)
  • FerwanaM. et al.

    Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

    Diabet Med

    (2013)
  • FonsecaV.A. et al.

    Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

    Diabetes Obes Metab

    (2010)
  • DefronzoR.A.

    Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes

    Diabetes Care

    (2011)
  • GazianoJ.M. et al.

    Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

    Diabetes Care

    (2010)
  • NislyS.A. et al.

    Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes

    Am J Health Syst Pharm

    (2013)
  • OwensD.R. et al.

    Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study

    Diabetes Obes Metab

    (2011)
  • LankischM.R. et al.

    Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs

    Diabetes Obes Metab

    (2008)
  • RiddleM.C. et al.

    The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

    Diabetes Care

    (2003)
  • HermansenK. et al.

    A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes

    Diabetes Care

    (2006)
  • RosenstockJ. et al.

    Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

    Diabetes Care

    (2005)
  • HomeP.D. et al.

    Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine

    Diabetes Obes Metab

    (2010)
  • Cited by (180)

    View all citing articles on Scopus
    View full text